Rosiglitazone Maleate | CAS#155141-29-0 | PPAR gamma activator

MedKoo Cat#: 562848 | Name: Rosiglitazone Maleate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rosiglitazone Maleate is a potent and selective activator of peroxisome proliferator-activated receptor gamma (PPAR gamma). It also acts as a potent orally active insulin sensitizing agent.

Chemical Structure

Rosiglitazone Maleate

CAS#155141-29-0 (maleate)

Theoretical Analysis

MedKoo Cat#: 562848

Name: Rosiglitazone Maleate

CAS#: 155141-29-0 (maleate)

Chemical Formula: C22H23N3O7S

Exact Mass: 0.0000

Molecular Weight: 473.50

Elemental Analysis: C, 55.81; H, 4.90; N, 8.87; O, 23.65; S, 6.77

Price and Availability

Size	Price	Availability
100mg	USD 150.00	Ready to ship
250mg	USD 250.00	Ready to ship
500mg	USD 385.00	Ready to ship
1g	USD 550.00	Ready to ship
2g	USD 850.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

155141-29-0 (maleate) 122320-73-4 (free base) 316371-84-3 (potassium)

Synonym

Rosiglitazone Maleate; Avandia; Avandaryl; BRL-49653C; BRL49653C; BRL 49653C; BRL-49653-C;

IUPAC/Chemical Name

5-[[4-[2-[Methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione maleate

InChi Key

SUFUKZSWUHZXAV-BTJKTKAUSA-N

InChi Code

InChI=1S/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1-

SMILES Code

O=C(N1)SC(CC2=CC=C(OCCN(C)C3=NC=CC=C3)C=C2)C1=O.O=C(O)/C=C\C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#C9B11B11

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Rosiglitazone maleate is an agonist of the peroxisome proliferator-activated receptor-γ (PPAR-γ) with an IC50 of 42 nM.

In vitro activity:

To determine the effect of RSG (Rosiglitazone) on kidney epithelial cells (MDCK cells) treated with oxalate, their viability and proliferation were measured by CCK-8 assays. MDCK cell exposure to oxalate led to a prominent concentration-dependent suppression of cell viability. Compared to that in the control group, cell viability was significantly decreased at oxalate concentrations greater than 0.5 mM. As shown in Figure 1(a), RSG is not toxic to cells at a range of concentrations. However, RSG inhibited cell viability distinctly at concentrations greater than 8 μmol/L. To determine the function of RSG in oxalate-induced MDCK cell injury, MDCK cells were treated with gradient concentrations of RSG and 0.5 mM oxalate for 1, 2, or 4 h. Importantly, peak protection occurred after exposure to an RSG concentration of 4 μM for 2 and 4 h; nevertheless, treatment with 5 μM or higher RSG for 2 h significantly inhibited MDCK cell viability, as presented in Figure 1(b). Reference: Oxid Med Cell Longev. 2019 Nov 12;2019:4826525. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875173/

In vivo activity:

The effect of the PPAR γ agonist rosiglitazone in protecting against pilocarpine-induced status epileptic resulting from over-activation was examined in vivo. Male C57BL/6 mice were assigned to three groups: the control group, pilocarpine-induced (SE) group, and rosiglitazone-treated (SE+Rosi) group. the expression of proinflammatory CD86 and iNOS was increased and that the expression of antiinflammatory CD206 and Arg-1 was decreased in the brains of pilocarpine-induced SE mice compared to control mice. Rosiglitazone treatment significantly inhibited the proinflammatory polarization of microglia and rescued neuron loss in the temporal lobe and hippocampi of the brain after SE. Reference: CNS Neurosci Ther. 2019 Dec;25(12):1363-1372. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887926/

	Solvent	mg/mL	mM
Solubility
	DMF	10.0	21.10
	DMSO	3.0	6.30

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 473.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Liu YD, Yu SL, Wang R, Liu JN, Jin YS, Li YF, An RH. Rosiglitazone Suppresses Calcium Oxalate Crystal Binding and Oxalate-Induced Oxidative Stress in Renal Epithelial Cells by Promoting PPAR-γ Activation and Subsequent Regulation of TGF-β1 and HGF Expression. Oxid Med Cell Longev. 2019 Nov 12;2019:4826525. doi: 10.1155/2019/4826525. PMID: 31781338; PMCID: PMC6875173. 2. Ji XX, Ji XJ, Li QQ, Lu XX, Luo L. Rosiglitazone Reduces Apoptosis and Inflammation in Lipopolysaccharide-Induced Human Umbilical Vein Endothelial Cells. Med Sci Monit. 2018 Sep 6;24:6200-6207. doi: 10.12659/MSM.910036. PMID: 30185768; PMCID: PMC6140784. 3. Peng J, Wang K, Xiang W, Li Y, Hao Y, Guan Y. Rosiglitazone polarizes microglia and protects against pilocarpine-induced status epilepticus. CNS Neurosci Ther. 2019 Dec;25(12):1363-1372. doi: 10.1111/cns.13265. Epub 2019 Nov 14. PMID: 31729170; PMCID: PMC6887926. 4. Deng J, Xia Y, Zhou Q, Wang X, Xiong C, Shao X, Shao M, Zou H. Protective effect of rosiglitazone on chronic renal allograft dysfunction in rats. Transpl Immunol. 2019 Jun;54:20-28. doi: 10.1016/j.trim.2019.01.002. Epub 2019 Jan 22. PMID: 30682409.

In vitro protocol:

In vivo protocol:

1. Peng J, Wang K, Xiang W, Li Y, Hao Y, Guan Y. Rosiglitazone polarizes microglia and protects against pilocarpine-induced status epilepticus. CNS Neurosci Ther. 2019 Dec;25(12):1363-1372. doi: 10.1111/cns.13265. Epub 2019 Nov 14. PMID: 31729170; PMCID: PMC6887926. 2. Deng J, Xia Y, Zhou Q, Wang X, Xiong C, Shao X, Shao M, Zou H. Protective effect of rosiglitazone on chronic renal allograft dysfunction in rats. Transpl Immunol. 2019 Jun;54:20-28. doi: 10.1016/j.trim.2019.01.002. Epub 2019 Jan 22. PMID: 30682409.

1: Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017 May 1;177(5):633-640. doi: 10.1001/jamainternmed.2016.9607. PubMed PMID: 28241279; PubMed Central PMCID: PMC5470366. 2: Xu D, Cai L, Guo S, Xie L, Yin M, Chen Z, Zhou H, Su Y, Zeng Z, Zhang X. Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database. Bioorg Med Chem Lett. 2017 Feb 15;27(4):1055-1061. doi: 10.1016/j.bmcl.2016.12.058. Epub 2016 Dec 26. PubMed PMID: 28089347. 3: Zou Z, He D, Cai L, He X, Wang K, Yang X, Li L, Li S, Su X. Alizarin Complexone Functionalized Mesoporous Silica Nanoparticles: A Smart System Integrating Glucose-Responsive Double-Drugs Release and Real-Time Monitoring Capabilities. ACS Appl Mater Interfaces. 2016 Apr 6;8(13):8358-66. doi: 10.1021/acsami.5b12576. Epub 2016 Mar 25. PubMed PMID: 26998551. 4: Cetinkalp S, Simsir IY, Sahin F, Saydam G, Ural AU, Yilmaz C. Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment? Saudi Pharm J. 2015 Jan;23(1):14-21. doi: 10.1016/j.jsps.2013.12.009. Epub 2013 Dec 22. PubMed PMID: 25685038; PubMed Central PMCID: PMC4310998. 5: Mohd-Radzman NH, Ismail WI, Jaapar SS, Adam Z, Adam A. Stevioside from Stevia rebaudiana Bertoni Increases Insulin Sensitivity in 3T3-L1 Adipocytes. Evid Based Complement Alternat Med. 2013;2013:938081. doi: 10.1155/2013/938081. Epub 2013 Dec 11. Erratum in: Evid Based Complement Alternat Med. 2016;2016:2467420. PubMed PMID: 24391675; PubMed Central PMCID: PMC3874339. 6: Attia AK, Ibrahim MM, El-Ries MA. Thermal analysis of some antidiabetic pharmaceutical compounds. Adv Pharm Bull. 2013;3(2):419-24. doi: 10.5681/apb.2013.067. Epub 2013 Aug 20. PubMed PMID: 24312870; PubMed Central PMCID: PMC3848208. 7: Zhao H, Li Z, Tian G, Gao K, Li Z, Zhao B, Wang J, Luo L, Pan Q, Zhang W, Wu Z, Chen J, Wang W. Effects of traditional Chinese medicine on rats with Type II diabetes induced by high-fat diet and streptozotocin: a urine metabonomic study. Afr Health Sci. 2013 Sep;13(3):673-81. doi: 10.4314/ahs.v13i3.22. PubMed PMID: 24250306; PubMed Central PMCID: PMC3824434. 8: Zhang Y, Huang X, Liu W, Cheng Z, Chen C, Yin L. Analysis of drugs illegally added into Chinese traditional patent medicine using surface-enhanced Raman scattering. Anal Sci. 2013;29(10):985-90. PubMed PMID: 24107564. 9: Mahgoub H, Youssef RM, Korany MA, Khamis EF, Kamal MF. Development and validation of spectrophotometric and HPTLC methods for simultaneous determination of rosiglitazone maleate and metformin hydrochloride in the presence of interfering matrix excipients. Drug Dev Ind Pharm. 2014 Sep;40(9):1190-8. doi: 10.3109/03639045.2013.810634. Epub 2013 Jul 8. PubMed PMID: 23829222. 10: Yavasoglu I, Sargin G, Kadikoylu G, Karul A, Bolaman Z. The activity of atorvastatin and rosiglitazone on CD38, ZAP70 and apoptosis in lymphocytes of B-cell chronic lymphocytic leukemia in vitro. Med Oncol. 2013;30(3):603. doi: 10.1007/s12032-013-0603-y. Epub 2013 May 19. PubMed PMID: 23686733. 11: Sherje AP, Desai KJ. Spectrophotometric Determination of Poorly Water Soluble Drug Rosiglitazone Using Hydrotropic Solubilization technique. Indian J Pharm Sci. 2011 Sep;73(5):579-82. doi: 10.4103/0250-474X.99021. PubMed PMID: 22923874; PubMed Central PMCID: PMC3425073. 12: Rane BR, Gujarathi NA, Patel JK. Biodegradable anionic acrylic resin based hollow microspheres of moderately water soluble drug rosiglitazone maleate: preparation and in vitro characterization. Drug Dev Ind Pharm. 2012 Dec;38(12):1460-9. doi: 10.3109/03639045.2011.653811. Epub 2012 Feb 23. PubMed PMID: 22356275. 13: Xu D, Xu M, Lin L, Rao S, Wang J, Davey AK. The effect of isosteviol on hyperglycemia and dyslipidemia induced by lipotoxicity in rats fed with high-fat emulsion. Life Sci. 2012 Jan 2;90(1-2):30-8. doi: 10.1016/j.lfs.2011.10.010. Epub 2011 Oct 26. PubMed PMID: 22075495. 14: Farouk M, Abdel-Satar O, Abdel-Aziz O, Shaaban M. Validated spectrophotometric methods for determination of some oral hypoglycemic drugs. Drug Discov Ther. 2011 Feb;5(1):41-52. PubMed PMID: 22466095. 15: Song GY, Gao Y, Wang C, Hu SG, Wang J, Qu DM, Ma HJ. Rosiglitazone reduces fatty acid translocase and increases AMPK in skeletal muscle in aged rats: a possible mechanism to prevent high-fat-induced insulin resistance. Chin Med J (Engl). 2010 Sep;123(17):2384-91. PubMed PMID: 21034554. 16: Li J, Meng X, Fan X, Lai X, Zhang Y, Zeng Y. [Pharmacodyamic material basis of rhizoma coptidis on insulin resistance]. Zhongguo Zhong Yao Za Zhi. 2010 Jul;35(14):1855-8. Chinese. PubMed PMID: 20939284. 17: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jul-Aug;32(6):437-61. doi: 10.1358/mf.2010.32.6.1538165. PubMed PMID: 20852754. 18: Hu LD, Xing QB, Shang C, Liu W, Liu C, Luo ZL, Xu HX. Preparation of rosiglitazone maleate sustained-release floating microspheres for improved bioavailability. Pharmazie. 2010 Jul;65(7):477-80. PubMed PMID: 20662314. 19: Lakshminarayana N, Prasad YR, Gharat L, Thomas A, Narayanan S, Raghuram A, Srinivasan CV, Gopalan B. Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur J Med Chem. 2010 Sep;45(9):3709-18. doi: 10.1016/j.ejmech.2010.05.020. Epub 2010 May 15. PubMed PMID: 20627471. 20: Wittayalertpanya S, Chompootaweep S, Thaworn N, Khemsri W, Intanil N. Pharmacokinetic and bioequivalence study of an oral 8 mg dose of rosiglitazone tablets in Thai healthy volunteers. J Med Assoc Thai. 2010 Jun;93(6):722-8. PubMed PMID: 20572378.